Clinical Trials and Research

Hereditary transthyretin amyloidosis (ATTRv) is a genetic disorder caused by more than 100 autosomal dominant mutations in the TTR gene. Owing to its marked…

Treatment shown to ease symptoms, reduce disability, improve quality of lifeAmvuttra (vutrisiran) safely and effectively eases symptoms, reduces disability,…

Swelling and fluid retention are common symptoms for individuals with transthyretin amyloid cardiomyopathy (ATTR-CM). This condition causes the heart muscle to…

In Las Vegas, Nevada, United States, DelveInsight's assessment reveals that globally, there are 10 key companies actively developing treatment therapies for AL…

Impact of disease-modifying therapies on imaging parameters in cardiac amyloidosis: A systematic review and meta-analysis.

LOS ANGELES - Immix Biopharma, Inc. (NASDAQ:IMMX) announced today the completion of enrollment in its NEXICART-2 trial, a Phase 2 study evaluating CAR-T therapy NXC…

Open-Label Extension of the ATTRibute-CM Randomized Clinical TrialKey PointsQuestion  Is long-term treatment with acoramidis in transthyretin amyloid…

LOS ANGELES, CA, March 30, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), the global leader in relapsed/refractory…

Analyses presented at ACC reinforce the totality of data for vutrisiran in patients with ATTR-CM including the impact on cardiovascular outcomes across a range of…

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like…